Health and Wellness NASDAQ brand, $3 million acquisition, $5 million stock buyback More: Jupiter Wellness (NASDAQ: JUPW)
Health and Wellness NASDAQ brand, $3 million acquisition, $5 million stock buyback Plus Featured on CNN, ABC, CBS, Bloomberg, Washington Post, Vogue and Forbes: Jupiter Wellness, Inc. JUPW
- Developer of CBD-based treatments for multiple skincare applications.
- New e-commerce and marketing team with experienced industry veterans.
- The JW-300 treatment has been shown to be effective in developing burns (sunburn) in a clinical trial.
- Acquisition of Ascent Clinical Research adding $3 million in annual revenue plus contribution to EBITDA.
- Exclusive worldwide rights to patented anti-shark technologies.
- A new combination treatment with cannabidiol and aspartame significantly reduces the ISGA score in atopic dermatitis.
- Exclusive worldwide rights to unique formulas treating Jellyfish and Man O’ War stings, sea lice and swimmer’s itch with 4 patents pending.
- Clinical trial of JW-200 for the treatment of actinic keratosis.
- $5.0 million share buyback program.
Jupiter Wellness, Inc. JUPW is a leading developer of cannabidiol (CBD) medical therapeutic and wellness products. the JUPW the clinical pipeline of prescription CBD-enhanced skincare therapeutic treatments addresses indications such as eczema, burns, herpetic cold sores and skin cancer. JUPW generates revenue from a growing line of exclusive over-the-counter skincare products, including its flagship CaniSun™ sunscreen and other wellness brands.
- JUPW Presents JW-300 Topical Burn Treatment at SCALE 2022 Aesthetic Medicine, Plastic Surgery and Medical Dermatology Conference
JUPW presented its JW-300, a topical cannabidiol treatment for first-degree burns, at the SCALE 2022 Aesthetic Medicine, Plastic Surgery & Medical Dermatology conference held May 11-15, 2022 in Nashville.
The results demonstrate the potential of JW-300 as a prescription or over-the-counter topical cream to help prevent sunburn and its consequences, including skin cancer.
- JUPW will offer clinical research services with the acquisition of Ascent Clinical Research: $3 million in annual revenue and contribution to EBITDA
April 27and JUPW announced that it has entered into an asset purchase agreement with Ascent Clinical Research, Inc. whereby it has acquired certain clinical assets, including clinical trial research contracts worth $3 million in annual revenue for a purchase price of 5% royalties on the future net income generated by the assets. This asset purchase agreement adds immediate revenue to JUPW in Q2 2022 and contributes positively to EBITDA with no upfront cash or share acquisition cost.
- JUPW appoints e-commerce and marketing team to drive sales of its growing portfolio of exclusive health and wellness brands
April 18and JUPW announced the appointment of three sales and marketing managers to its team.
JUPW has built a portfolio of award-winning wellness brands including CaniSun, fitCBD, Jack, Wellness CBD 1937, Black Belt CBD and Felix Ambrosia, as well as prescription therapeutics such as Photosil which have been featured in numerous media outlets including the Today Show, CNN, ABC, CBS, Animal Planet, AdWeek, Bloomberg, The Washington Post, Vogue, BuzzFeed and Forbes. Like JUPW continues to expand portfolio of clinically tested and science-backed wellness, over-the-counter and prescription products, new marketing team expected to drive revenue
Mohammed Ahmed is an experienced marketing professional specializing in market research, consumer behavior, social media marketing and demand generation.
Jennifer Canon is a research, development, and marketing specialist in the personal care, over-the-counter drug, prescription pharmaceutical, and topical care products industries at companies such as Hydron Technologies and Greyson International. she co-founded.
Guy Shapira is a seasoned digital marketer of nutraceutical, health and beauty products and services.
- JUPW to Launch CaniSun for Shark Defense Sunscreen with Patented Shark Repellents
Watch the Discovery Channel videos on anti-shark technology here: https://youtu.be/Hqp04gdAXyk and here: https://youtu.be/PM0YTlbx1qg
April 7and JUPW announced the upcoming launch of CaniSun for Shark Defense™, the latest addition to the company’s line of reef-friendly sunscreens. Through a licensing agreement with Shark Defense Technologies LLC, the leading researcher of chemical, electrochemical and magnetic shark repellents, JUPW holds exclusive worldwide rights to patents, formulas and production methods for anti-shark technologies for use in sunscreen and skincare products.
- A new combination treatment with cannabidiol and aspartame (JW-100) significantly reduces the ISGA score in atopic dermatitis: results of a randomized, double-blind, placebo-controlled interventional study
April 6and JUPW announced the publication of the results of a clinical study to investigate the safety and efficacy of JW-100, its proprietary lotion formulation for the treatment of atopic dermatitis (eczema) in the Journal of Cosmetic Dermatology, Vol. 21, number 4, April 2022, pages: 1647-1650.
- JUPW Launches Patent-Pending Formula-Backed NoStingz Jellyfish Protective Sunscreen Into $13 Billion Sunscreen Market
April 5and JUPW announced the launch of NoStingz, an exclusive line of sunscreens designed to protect against jellyfish and man-of-war stings, sea lice and swimmer’s itch while continuing to protect water lovers’ skin. ocean against UVA/UVB in a range of SPF. JUPW signed a licensing agreement with Shark Defense Technologies for exclusive worldwide intellectual property rights to formulas and production methods for jellyfish protective compounds, including 4 patents pending. The agreement provides for future collaboration to develop and refine additional formulas.
To learn more about The JUPW NoStingz product or to purchase visit: https://canisun.com/shop/nostingz-your-barrier-of-protection-from-sun-sea/
- JUPW Completes Enrollment in a Double-Blind, Placebo-Controlled Clinical Trial of JW-200 for the Treatment of Actinic Keratosis
February 18and JUPW announced that it has completed enrollment in its clinical trial of JW-200 for the treatment of actinic keratosis (AK), a common form of precancerous growths that typically appear as thick scaly lesions on sun-exposed skin. If left untreated, up to 15.1% of patients with 10 or more AK lesions will develop keratinocyte carcinoma.
- JUPW Board of Directors Approves $5.0 Million Share Repurchase Program
January 25and JUPW the announced that its board of directors has approved a $5.0 million share repurchase program which expires on June 30, 2022. Under the share repurchase program, the shares of JUPW Common Shares may be repurchased periodically in open market or over-the-counter transactions.
For more information about Jupiter Wellness, Inc. (JUPW) visit www.jupiterwellnessinc.com or
https://jupiterwellness.com/jupiter-wellness-inc-nasdaq-jupw-is-set-to-offer-clinical-research-services-with-the-3-million-dollar-acquisition-of-acquired-ascent-clinical-research/
WARNING: Products mentioned are THC-free and/or Farm Bill 2018 compliant.
This article is for informational purposes only and does not constitute a recommendation for the purchase or sale of stocks.
Media Contact
Company Name: Jupiter Wellness, Inc.
Contact person: Media Relations
E-mail: Send an email
Call: 561 244 7100
Address:725 North Highway A1A, Suite C-106
City: Jupiter
State: FL 33477
Country: United States
Website: https://jupiterwellness.com/jupiter-wellness-inc-nasdaq-jupw-is-set-to-offer-clinical-research-services-with-the-3-million-dollar-acquisition-of-acquired-ascent- clinical research/